{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T19:12:30Z","timestamp":1791054750717,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,9,26]],"date-time":"2013-09-26T00:00:00Z","timestamp":1380153600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cell Biochem Biophys"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1007\/s12013-013-9767-5","type":"journal-article","created":{"date-parts":[[2013,9,25]],"date-time":"2013-09-25T06:44:09Z","timestamp":1380091449000},"page":"65-69","source":"Crossref","is-referenced-by-count":13,"title":["Oxidized Low Density Lipoprotein and Inflammation in Gout Patients"],"prefix":"10.1007","volume":"69","author":[{"given":"Xingliang","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qibin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingguo","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,9,26]]},"reference":[{"key":"9767_CR1","doi-asserted-by":"crossref","first-page":"499","DOI":"10.7326\/0003-4819-143-7-200510040-00009","volume":"143","author":"HK Choi","year":"2005","unstructured":"Choi, H. K., Mount, D. B., Reginato, A. M., et al. (2005). Pathogenesis of gout. Annals of Internal Medicine, 143, 499\u2013516.","journal-title":"Annals of Internal Medicine"},{"key":"9767_CR2","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1161\/CIRCULATIONAHA.107.728600","volume":"116","author":"HK Choi","year":"2007","unstructured":"Choi, H. K., & Curhan, G. (2007). Independent impact of gout on mortality and risk for coronary heart disease. Circulation, 116, 880\u2013900.","journal-title":"Circulation"},{"issue":"5","key":"9767_CR3","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/MOL.0b013e32832fa58d","volume":"20","author":"Y Ishigaki","year":"2009","unstructured":"Ishigaki, Y., Oka, Y., & Katagiri, H. (2009). Circulating oxidized LDL: A biomarker and a pathogenic factor. Current Opinion in Lipidology, 20(5), 363\u2013369.","journal-title":"Current Opinion in Lipidology"},{"key":"9767_CR4","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.cccn.2003.09.019","volume":"339","author":"Z Tsutsumi","year":"2004","unstructured":"Tsutsumi, Z., Moriwaki, Y., Takahashi, S., et al. (2004). Oxidized low-density lipoprotein autoantibodies in patients with primary gout: Effect of urate-lowering therapy. Clinica Chimica Acta, 339, 117\u2013122.","journal-title":"Clinica Chimica Acta"},{"issue":"2","key":"9767_CR5","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/ar2952","volume":"12","author":"N Dalbeth","year":"2010","unstructured":"Dalbeth, N., & Haskard, D. O. (2010). Mechanisms of inflammation in gout. Arthritis Research and Therapy, 12(2), 206.","journal-title":"Arthritis Research and Therapy"},{"key":"9767_CR6","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/art.1780200320","volume":"20","author":"SL Wallace","year":"1977","unstructured":"Wallace, S. L., Robinson, H., Masi, A. T., et al. (1977). Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis and Rheumatism, 20, 895\u2013900.","journal-title":"Arthritis and Rheumatism"},{"issue":"Suppl. 5","key":"9767_CR7","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.3949\/ccjm.75.Suppl_5.S2","volume":"75","author":"HR Schumacher Jr","year":"2008","unstructured":"Schumacher, H. R., Jr. (2008). The pathogenesis of gout. Cleveland Clinic Journal of Medicine, 75(Suppl. 5), S2\u2013S4.","journal-title":"Cleveland Clinic Journal of Medicine"},{"key":"9767_CR8","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1093\/rheumatology\/keq037","volume":"49","author":"E Krishnan","year":"2010","unstructured":"Krishnan, E. (2010). Inflammation, oxidative stress and lipids: The risk triad for atherosclerosis in gout. Rheumatology (Oxford), 49, 1229\u20131238.","journal-title":"Rheumatology (Oxford)"},{"key":"9767_CR9","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/art.1780340203","volume":"34","author":"E Pascual","year":"1991","unstructured":"Pascual, E. (1991). Persistence of monosodium urate crystals and low-grade inflammation in the synovial fluid of patients with untreated gout. Arthritis and Rheumatism, 34, 141\u2013145.","journal-title":"Arthritis and Rheumatism"},{"key":"9767_CR10","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.cyto.2005.11.010","volume":"33","author":"T Inokuchi","year":"2006","unstructured":"Inokuchi, T., Moriwaki, Y., Tsutsui, H., et al. (2006). Plasma interleukin (IL)-18 (interferon-gamma-inducing factor) and other inflammatory cytokines in patients with gouty arthritis and monosodium urate monohydrate crystal-induced secretion of IL-18. Cytokine, 33, 21\u201327.","journal-title":"Cytokine"},{"key":"9767_CR11","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3109\/13506120209114817","volume":"9","author":"Y Kumon","year":"2002","unstructured":"Kumon, Y., Nakauchi, Y., Suehiro, T., et al. (2002). Proinflammatory cytokines but not acute phase serum amyloid A or C-reactive protein, downregulate paraoxonase 1 (PON1) expression by HepG2 cells. Amyloid, 9, 160\u2013164.","journal-title":"Amyloid"},{"key":"9767_CR12","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/978-1-60761-350-3_13","volume":"660","author":"B Mackness","year":"2010","unstructured":"Mackness, B., & Mackness, M. (2010). Anti-inflammatory properties of paraoxonase-1 in atherosclerosis. Advances in Experimental Medicine and Biology, 660, 143\u2013151.","journal-title":"Advances in Experimental Medicine and Biology"},{"issue":"1","key":"9767_CR13","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s12016-008-8095-9","volume":"37","author":"H Itabe","year":"2009","unstructured":"Itabe, H. (2009). Oxidative modification of LDL: Its pathological role in atherosclerosis. Clinical Reviews in Allergy and Immunology, 37(1), 4\u201311.","journal-title":"Clinical Reviews in Allergy and Immunology"},{"issue":"3","key":"9767_CR14","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.arcmed.2011.05.002","volume":"42","author":"PJ Kappelle","year":"2011","unstructured":"Kappelle, P. J., Bijzet, J., Hazenberg, B. P., & Dullaart, R. P. (2011). Lower serum paraoxonase-1 activity is related to higher serum amyloid a levels in metabolic syndrome. Archives of Medical Research, 42(3), 219\u2013225.","journal-title":"Archives of Medical Research"},{"issue":"4","key":"9767_CR15","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1194\/jlr.M600414-JLR200","volume":"48","author":"M Tabuchi","year":"2007","unstructured":"Tabuchi, M., Inoue, K., Usui-Kataoka, H., et al. (2007). The association of C-reactive protein with an oxidative metabolite of LDL and its implication in atherosclerosis. Journal of Lipid Research, 48(4), 768\u2013781.","journal-title":"Journal of Lipid Research"},{"issue":"5","key":"9767_CR16","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2143\/AC.59.5.2005219","volume":"59","author":"P Holvoet","year":"2004","unstructured":"Holvoet, P. (2004). Oxidized LDL and coronary heart disease. Acta Cardiologica, 59(5), 479\u2013484.","journal-title":"Acta Cardiologica"},{"key":"9767_CR17","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1002\/art.20317","volume":"50","author":"DR Yagnik","year":"2004","unstructured":"Yagnik, D. R., Evans, B. J., Florey, O., et al. (2004). Macrophage release of transforming growth factor beta1 during resolution of monosodium urate monohydrate crystal-induced inflammation. Arthritis and Rheumatism, 50, 2273\u20132280.","journal-title":"Arthritis and Rheumatism"},{"key":"9767_CR18","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1006\/abbi.1999.1491","volume":"372","author":"CX Santos","year":"1999","unstructured":"Santos, C. X., Anjos, E. I., & Augusto, O. (1999). Uric acid oxidation by peroxynitrite: Multiple reactions, free radical formation, and amplification of lipid oxidation. Archives of Biochemistry and Biophysics, 372, 285\u2013294.","journal-title":"Archives of Biochemistry and Biophysics"},{"key":"9767_CR19","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.bcp.2005.05.009","volume":"70","author":"N Kuzkaya","year":"2005","unstructured":"Kuzkaya, N., Weissmann, N., Harrison, D. G., et al. (2005). Interactions of peroxynitrite with uric acid in the presence of ascorbate and thiols: Implications for uncoupling endothelial nitric oxide synthase. Biochemical Pharmacology, 70, 343\u2013354.","journal-title":"Biochemical Pharmacology"},{"issue":"Pt 1","key":"9767_CR20","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1042\/0264-6021:3400143","volume":"340","author":"M Bagnati","year":"1999","unstructured":"Bagnati, M., Perugini, C., Cau, C., et al. (1999). When and why a water-soluble antioxidant becomes pro-oxidant during copper-induced low-density lipoprotein oxidation: A study using uric acid. Biochemical Journal, 340(Pt 1), 143\u2013152.","journal-title":"Biochemical Journal"},{"key":"9767_CR21","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1152\/ajpcell.00600.2006","volume":"293","author":"YY Sautin","year":"2007","unstructured":"Sautin, Y. Y., Nakagawa, T., Zharikov, S., et al. (2007). Adverse effects of the classical antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative\/nitrosative stress. American Journal of Physiology-Cell Physiology, 293, 584\u2013596.","journal-title":"American Journal of Physiology-Cell Physiology"},{"key":"9767_CR22","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1113\/jphysiol.2003.055913","volume":"16","author":"CE Berry","year":"2004","unstructured":"Berry, C. E., & Hare, J. M. (2004). Xanthine oxidoreductase and cardiovascular disease: Molecular mechanisms and pathophysiological implications. Journal of Physiology, 16, 589\u2013606.","journal-title":"Journal of Physiology"},{"key":"9767_CR23","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1111\/j.1523-1755.2005.00273.x","volume":"67","author":"UM Khosla","year":"2005","unstructured":"Khosla, U. M., Zharikov, S., Finch, J. L., et al. (2005). Hyperuricemia induces endothelial dysfunction. Kidney International, 67, 1739\u20131742.","journal-title":"Kidney International"},{"key":"9767_CR24","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.pupt.2005.01.002","volume":"18","author":"Y Komaki","year":"2005","unstructured":"Komaki, Y., Sugiura, H., Koarai, A., et al. (2005). Cytokine-mediated xanthine oxidase upregulation in chronic obstructive pulmonary disease\u2019s airways. Pulmonary Pharmacology & Therapeutics, 18, 297\u2013302.","journal-title":"Pulmonary Pharmacology & Therapeutics"},{"key":"9767_CR25","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1093\/eurheartj\/ehi879","volume":"27","author":"C Ruggiero","year":"2006","unstructured":"Ruggiero, C., Cherubini, A., Ble, A., et al. (2006). Uric acid and inflammatory markers. European Heart Journal, 27, 1174\u20131181.","journal-title":"European Heart Journal"},{"issue":"2","key":"9767_CR26","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1136\/ard.54.2.90","volume":"54","author":"S Takahashi","year":"1995","unstructured":"Takahashi, S., Yamamoto, T., Moriwaki, Y., et al. (1995). Increased concentrations of serum Lp(a) lipoprotein in patients with primary gout. Annals of the Rheumatic Diseases, 54(2), 90\u201393.","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"12","key":"9767_CR27","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/S0006-2952(02)01018-3","volume":"63","author":"L Tatidis","year":"2002","unstructured":"Tatidis, L., Masquelier, M., & Vitols, S. (2002). Elevated up take of low density lipoprotein by drug resistant human leukemic cell lines. Biochemical Pharmacology, 63(12), 2169\u20132180.","journal-title":"Biochemical Pharmacology"}],"container-title":["Cell Biochemistry and Biophysics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12013-013-9767-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12013-013-9767-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12013-013-9767-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T19:16:10Z","timestamp":1553627770000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12013-013-9767-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,26]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["9767"],"URL":"https:\/\/doi.org\/10.1007\/s12013-013-9767-5","relation":{},"ISSN":["1085-9195","1559-0283"],"issn-type":[{"value":"1085-9195","type":"print"},{"value":"1559-0283","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,26]]}}}